Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients

Methotrexate (MTX) is known as a first-line synthetic disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Although the risk of LPD development increases by RA inflammation itself, observation of spontaneous regression of LPD after MTX discontinuation lead to...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Shuntaro, Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954173/
https://www.ncbi.nlm.nih.gov/pubmed/31866617
http://dx.doi.org/10.3960/jslrt.19028
_version_ 1783486754007810048
author Saito, Shuntaro
Takeuchi, Tsutomu
author_facet Saito, Shuntaro
Takeuchi, Tsutomu
author_sort Saito, Shuntaro
collection PubMed
description Methotrexate (MTX) is known as a first-line synthetic disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Although the risk of LPD development increases by RA inflammation itself, observation of spontaneous regression of LPD after MTX discontinuation lead to the theory of lymphomagenic role of MTX. In this review, we focused on the several immune response involved in LPD that developed under MTX administration in RA patients.
format Online
Article
Text
id pubmed-6954173
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher JSLRT
record_format MEDLINE/PubMed
spelling pubmed-69541732020-01-13 Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients Saito, Shuntaro Takeuchi, Tsutomu J Clin Exp Hematop Review Article Methotrexate (MTX) is known as a first-line synthetic disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Although the risk of LPD development increases by RA inflammation itself, observation of spontaneous regression of LPD after MTX discontinuation lead to the theory of lymphomagenic role of MTX. In this review, we focused on the several immune response involved in LPD that developed under MTX administration in RA patients. JSLRT 2019-12-22 /pmc/articles/PMC6954173/ /pubmed/31866617 http://dx.doi.org/10.3960/jslrt.19028 Text en © 2019 by The Japanese Society for Lymphoreticular Tissue Research https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License.
spellingShingle Review Article
Saito, Shuntaro
Takeuchi, Tsutomu
Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
title Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
title_full Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
title_fullStr Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
title_full_unstemmed Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
title_short Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
title_sort immune response in lpd during methotrexate administration (mtx-lpd) in rheumatoid arthritis patients
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954173/
https://www.ncbi.nlm.nih.gov/pubmed/31866617
http://dx.doi.org/10.3960/jslrt.19028
work_keys_str_mv AT saitoshuntaro immuneresponseinlpdduringmethotrexateadministrationmtxlpdinrheumatoidarthritispatients
AT takeuchitsutomu immuneresponseinlpdduringmethotrexateadministrationmtxlpdinrheumatoidarthritispatients

Ejemplares similares